Bradykinin, 1-100 Mg/ml, produced a rapid rise in the concentration of 3':5'-guanosine monophosphate (cyclic GMP) and 3':5'-adenosine monophosphate (cyclic AMP) in slices of guinea pig lung. Concentrations of both nucleotides reached a maximum in about 2 min, then declined to basal levels in 6-12 min. The transient nature of the effect was presumably due to the rapid destruction of bradykinin as evidenced by (1) reaccumulation of nucleotides when bradykinin was added a second time, and (2) potentiation of the bradykinin effects by pyroGluLys-Trp-Ala-Pro, a peptide that inhibits inactivation of bradykinin by kininase. It has been reported elsewhere that histamine, prostaglandins E1 and E2, and j3-adrenergic stimulation can cause accumulation of cyclic AMP in lung slices without affecting cyclic GMP concentration, whereas acetylcholine increases the concentrations of both cyclic GMP and cyclic AMP. Thus it was possible that the effects of bradykinin were indirect, i.e., secondary to release of one or more of these compounds. Promethazine (an antihistamine), propranolol (a fl-adrenergic blocking agent) and atropine (an anticholinergic agent) did not alter basal cyclic nucleotide concentrations or the effects of bradykinin. Two inhibitors of prostaglandin synthesis, indomethacin and aspirin, which alone were without effect, in the presence of bradykinin completely prevented the rise in cyclic AMP but did not interfere with cyclic GMP accumulation. Similarly, the effect of acetylcholine on cyclic AMP was abolished by indomethacin while that on cyclic GMP was unaltered. We suggest that in lung and probably in other tissues, bradykinin, acetylcholine, and perhaps other stimuli enhance the synthesis and release of prostaglandins as one of the consequences of their effects on cyclic GMP metabolism.
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We have recently found (1) that acetylcholine increases the 3': 5' cyclic GMP content of guinea pig lung slices, as it does also in slices of heart (2), brain (2) , intestinal smooth muscle (3), and thyroid (4) . In contrast to its effects in other tissues (2, 3, 5) , however, acetylcholine also elevated the 3': 5' cyclic AMP content of the lung slices. As reported below, bradykinin similarly causes accumulation of both cyclic nucleotides in lung slices, and it appears that the effects of these agents on cyclic AMP are secondary to the induced release of prostaglandin(s). The data presented are consistent with our view that cyclic GMP plays a role in the regulation of prostaglandin synthesis and release. 
METHODS
Lungs were obtained from female N.I.H. strain guinea pigs (200-400 g) and slices prepared as described elsewhere (1) . After collection of slices in Krebs' Ringer's bicarbonate medium, pH 7.4, at 370, through which 02:CO2, 95:5, was bubbled, portions (200-400 mg wet weight) were placed in 25 ml Erlenmeyer flasks containing 3 ml of the same medium with 1 mM theophylline and incubated for 15 min at 370 in the same atmosphere of 02:CO2. Additions, in a total volume of 30 ul, were then made and at the indicated time thereafter, incubations were terminated by addition of 5 ml of 10% trichloroacetic acid. Tissue extracts were prepared as described previously (1), and protein content of the trichloroacetic-acid precipitates determined by the method of Lowry et al. (6) .
Each extract was divided into two parts for purification and assay of cyclic GMP and cyclic AMP. Portions for cyclic GMP analysis, after the addition of cyclic[3H] GMP (<1 pmol), were extracted with water-saturated ether and neutralized with 1 N NaOH. Tris* HCl buffer, pH 7.4, was added to a concentration of 5 mM and the samples were applied to 0.5 X 3-cm column of neutral alumina, which were eluted with 6 ml of the same buffer. The eluates were applied to 0.5 X 3-cm columns of Dowex AG 1 X 8 formate (200-400 mesh), which were eluted as previously described (7) . The 4 N formic-acid eluates were lyophilized and the residue dissolved in 300 ,ul of distilled water. The cyclic GMP content of the purified samples was determined by the radioimmunoassay of Steiner et al. (8) . The values reported here have been corrected on the basis of the recovery of cyclic [8H] GMP in each sample, which ranged from 60 to 80%. Incubation of representative samples with cyclic 3':5'-nucleotide phosphodiesterase before assay produced greater than 95% hydrolysis of cyclic GMP in all cases.
Cyclic AMP was purified from samples of tissue extracts as previously described (9) and assayed by the method of Gilman (10 
RESULTS
In 10 experiments, the cyclic GMP content of lung slices incubated for 15 min with 1 mM theophylline was 3.30 0.26 pmol/mg of protein (mean SE). Two minutes after the addition of bradykinin, 10 ug/ml, this was increased 3.27 0.64 pmol/mg of protein (mean of differences between pairs 4 SE). At the same time bradykinin increased the cyclic AMP content 60.5 : 4.6 pmol/mg of protein (mean of paired differences SE) from a basal level of 12.5 4 0.7. As shown in Fig. 1 , the effects of bradykinin at a concentration of 1 .ug/ml were roughly half of those produced by 10 ,gg/ml. In other experiments (also with a 2-min exposure to bradykinin) 100 ug/ml caused somewhat larger increases than 10 ,sg/ml in both nucleotides; 0.1 Ag/ml was without effect.
Six minutes after the addition of bradykinin, the concentrations of cyclic GMP and cyclic AMP were much lower than they were after 2 min, and by 12 min both nucleotides had returned to basal levels (Fig. 2) . When bradykinin was added for a second time either 4 or 10 min after the first addition, the cyclic GMP concentration 2 min later was essentially at the same level as it was 2 min after the initial exposure. On the other hand, the cyclic AMP concentration 2 min after second addition of bradykinin was not elevated to the same extent as it was after the first (Fig. 2) . As shown in Fig. 3 , the bradykinin-potentiating peptide, which alone had no effect on cyclic nucleotide concentrations, enhanced the effects of bradykinin, 10 ,g/ml, on both cyclic GMP and cyclic AMP.
Bradykinin, lysylbradykinin (kallidin), and methionyllysylbradykinin produced similar effects on the cyclic GMP and cyclic AMP content of lung slices ( As shown in Table 2 , Exps. 1 and 2, the effects of bradykinin were not influenced by promethazine, an antihistamine, or by propranolol, a ,B-adrenergic blocking agent. In the presence of indomethacin or aspirin, however, bradykinin produced no increase in cyclic AMP concentration, while the cyclic GMP response was apparently unaltered. These drugs had no effect on basal levels of the nucleotides, and 0.5% ethanol (the concentration present in the medium when indomethacin was added) was without effect whether or not bradykinin was present. Indomethacin did not interfere with Indomethacin also prevented the rise in cyclic AMP produced by acetylcholine, without interfering with its action on cyclic GMP (Table 2, Exp. 3). The effects of acetylcholine on both nucleotides were prevented by promethazine, an example, perhaps of anticholinergic properties exhibited by many antihistamines (11) . Promethazine completely inhibited the effect of histamine on cyclic GMP and partially inhibited that on cyclic AMP. DISCUSSION It is apparent that the concentrations of bradykinin required to induce transient accumulation of cyclic GMP and cyclic AMP in lung slices are much higher than those found in mammalian blood (12) . Clearly, however, even the relatively large amounts added in these experiments were rapidly destroyed, as evidenced by (1) reaccumulation of cyclic nucleotides when fresh bradykinin was added for a second time during the incubation period, and (2) potentiation of bradykinin effects by the peptide, pyroGlu-Lys-Trp-Ala-Pro, which inhibits the kininase that inactivates bradykinin (13) .
The effects of bradykinin on cyclic GMP and cyclic AMP in lung slices are similar to those of acetycholine (1), but were not inhibited by atropine as might have been expected if they were secondary to the release of endogenous acetylcholine. Even in the presence of an apparently maximally efeffective concentration of acetylcholine, bradykinin further increased the concentrations of the cyclic nucleotides. Nevertheless, given the rapidity and transitory nature of the effects (14) and counteract the bradykinin-stimulated release of of PGE2, PGF2a, and "rabbit aortic contracting substance" from perfused lung (14, 15) . Prostaglandins El and E2 cause accumulation of cyclic AMP in lung slices (1) , presumably by enhancing adenylate cyclase activity, as they do in many types of cells. Whether PGF2a or the aorta contracting substance, which may be identical with the endoperoxide intermediate in of these agents, it would be unwise to conclude that they act prostaglandin synthesis (16) , can do so also, remains to be determined. It has been reported that acetylcholine can stimulate release of prostaglandins from the adrenal (17) and it seems probable that this occurred also in the lung slices, where indomethacin abolished the effect of acetylcholine on cyclic AMP but apparently did not alter the cyclic GMP response.
We would suggest that the enhancement of prostaglandin synthesis and release caused by bradykinin (15) , acetylcholine (17) , and perhaps by histamine (15) and other stimuli is one of the consequences of the effects of such agents on cyclic GMP metabolism. Possibly in many types of cells elevation of cyclic GMP concentration is a signal for increased synthesis and release of prostaglandins. Within the framework of this hypothesis, there are many obvious reasons why, in some tissues, an increase in cyclic GMP content might not be accompanied by a demonstrable rise in cyclic AMP. The latter would require that, in addition to cells that can accumulate cyclic GM\P in response to bradykinin (oracetylcholine orother stimuli), there be cells that have the ability to produce prostaglandins and cells that can accumulate detectable amounts of cyclic AMP in response to the prostaglandins produced. Thus, the composition of the tissue, in terms of the numbers and respective capacities of different types of cells, would determine just how far this train of events would progress or be discernable. It was noted, for example, in the experiment shown in Fig. 2 , that a second addition of bradykinin was essentially as effective as the first in elevating the cyclic GMP concentration of lung slices but the initial rise in cyclic AMP was apparently not duplicated. This might be due to decreased synthesis of prostaglandins (either related or unrelated to the repeated stimulus) or could reflect a diminished capacity to accumulate cyclic AMP in response to continued or repeated hormonal stimulation, as has been observed in other systems, e.g., fat cells (18, 19) , and brain slices (20) .
Because of the cellular heterogeneity of the lung, it would be difficult if not impossible to determine in lung slices whether the changes in concentrations of cyclic GMP, prostaglandin(s), and cyclic AMP occur in the same or in different cells. In order to answer such questions and to define more precisely the postulated role of cyclic GMP in prostaglandin synthesis, homogeneous populations of cells are employed in current studies.
